<DOC>
	<DOCNO>NCT02094430</DOCNO>
	<brief_summary>The aim study evaluate clinical pharmacology , efficacy safety FGTW pediatric patient congenital fibrinogen deficiency .</brief_summary>
	<brief_title>Human Fibrinogen Concentrate ( FGTW ) Pediatric Patients With Congenital Fibrinogen Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Signed date informed consent form parent legal representative Age le equal 12 year old Patients inherit afibrinogenemia severe inherit hypofibrinogenemia Negative result HCGbased pregnancy test female childbearing potential ( presence menstruation ) Dysfibrinogenemia Acquired fibrinogen deficiency Suspected present past anticoagulation inhibitor Personal history venous arterial thrombosis thromboembolic event Comorbidity other/unrelated coagulopathies Administration fibrinogen concentrate fibrinogen contain blood product last 15 day Permanent treatment antithrombotic antiplatelet agent heparins , antiIIa antiXa agent , aspirin , clopidogrel NSAIDs .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>